One Stop Target-to-Hit Platform: RAS Family

The RAS family of small GTPases are among the most frequently mutated oncogenes in human cancer. Previously viewed as undruggable, the recent FDA approval of two KRAS G12C-selective inhibitors has offered real promise to the development of anti-RAS therapies, including mutation-specific strategies.

To support the discovery of novel KRAS inhibitors, WuXi AppTec offers a comprehensive panel of ready-to-go biophysical assays, nucleotide exchange assays, and established X-ray crystallography protocols.  Our RAS protein production platform encompasses a broad range of KRAS variants, including G12C, G12D, G12V, and “Cys-light” variants to study covalent inhibitors.

Target of the month_RAS family

Download